- Home
- LPLA vs INM Comparison
LPLA vs INM Comparison
Compare LPLA & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- INM
- Stock Information
- Founded
- LPLA 1989
- INM 1981
- Country
- LPLA United States
- INM Canada
- Employees
- LPLA N/A
- INM N/A
- Industry
- LPLA Investment Bankers/Brokers/Service
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- LPLA Finance
- INM Health Care
- Exchange
- LPLA Nasdaq
- INM Nasdaq
- Market Cap
- LPLA 30.4B
- INM 3.2M
- IPO Year
- LPLA 2010
- INM N/A
- Fundamental
- Price
- LPLA $378.49
- INM $2.73
- Analyst Decision
- LPLA Strong Buy
- INM
- Analyst Count
- LPLA 14
- INM 0
- Target Price
- LPLA $379.79
- INM N/A
- AVG Volume (30 Days)
- LPLA 662.6K
- INM 5.7M
- Earning Date
- LPLA 07-24-2025
- INM 05-12-2025
- Dividend Yield
- LPLA 0.31%
- INM N/A
- EPS Growth
- LPLA 9.05
- INM N/A
- EPS
- LPLA 14.44
- INM N/A
- Revenue
- LPLA $12,896,160,000.00
- INM $4,920,990.00
- Revenue This Year
- LPLA $29.17
- INM N/A
- Revenue Next Year
- LPLA $17.00
- INM N/A
- P/E Ratio
- LPLA $26.57
- INM N/A
- Revenue Growth
- LPLA 25.70
- INM N/A
- 52 Week Low
- LPLA $187.19
- INM $1.72
- 52 Week High
- LPLA $390.23
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- LPLA 53.58
- INM 45.89
- Support Level
- LPLA $376.93
- INM $2.66
- Resistance Level
- LPLA $384.15
- INM $5.50
- Average True Range (ATR)
- LPLA 9.55
- INM 0.35
- MACD
- LPLA 0.46
- INM -0.05
- Stochastic Oscillator
- LPLA 79.75
- INM 14.51
About LPLA LPL Financial Holdings Inc.
LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. As of the end of 2024, the company had over 29,000 advisors on its platform managing $1.7 trillion of client assets. The company doesn't have material operations outside the United States.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.